Abstract 374P
Background
Oral lichen planus (OLP) is an autoimmune disorder that causes a persistent inflammatory condition that affects the oral mucosa. The precise cause of OLP is unknown, however it is thought to be a combination of genetic predisposition, environmental factors, and immunological dysregulation. Oral lichen planus is classified as a potentially oral malignant lesion (POML) because it has the potential to develop into oral squamous cell cancer (OSCC).
Methods
34 individuals with OLP were followed for three years in this prospective clinic-histologic investigation. Tissue samples from these patients were immunohistochemically and histomorphometrically examined for CD34 and CD105 (Endoglin). The patients received routine oral preventive therapy at three-month intervals and were followed for up to three years. The possibility for a malignant transformation was evaluated clinically, and in the event of clinical suspicion, a repeat biopsy was undertaken to rule out malignancy.
Results
The clinical and histological parameters were analyzed using the paired 't' test with the assumption of normal distribution and with an appropriate sample size of 34. During the three-year follow-up period, 73% (n=25/34) of the total patients never developed oral cancer. OSCC was the most typically found, with the Gingivo-Buccal Sulcus area being the most prevalent site. The mean Vascular Caliber (VC) utilizing CD 34 and CD 105 (μm2) in PMOL was 8.5 ± 2.0 μm2 and 5.4 ± 1.2 μm2, respectively. The mean VC - CD 34 and CD105 did differ statistically (p-value<0.05). It has been reported that patients with 'erosive' OLP had a higher malignant transformation potential (n=09/34) and higher levels of CD34 and CD105 than patients without malignant transformation (p-value<0.01).
Conclusions
CD 34 and CD105 markers were found to be beneficial in predicting the malignant transformation potential of Erosive OLP when utilized in evaluating micro vessel density and vessel morphometry. This suggests that CD34 and CD105 may be useful immunohistological indicators for assessing the early stage of malignant transformation potential in POMLs, particularly OLP, well before 3.0 years. As a result, CD34 and Endoglin are being recommended as IHC Panel Markers for determining OLP prognosis.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
462P - Cognitive function of survivors with non-central nervous system cancer and its correlates: A community rehabilitation perspective
Presenter: Ann Kuo
Session: Poster Display
Resources:
Abstract
463P - The use of antipsychotic for managing delirium in patients with cancer
Presenter: Natasya Reina
Session: Poster Display
Resources:
Abstract
464P - The prevalence and correlates of frailty and pre-frailty in elderly patients with breast cancer: A cross-sectional study from China
Presenter: Min Xiao
Session: Poster Display
Resources:
Abstract
465P - Oncological care needs of people with mental illness: A single institution experience in Australia
Presenter: Hui Ling Yeoh
Session: Poster Display
Resources:
Abstract
466P - Identification of patient satisfaction predictors among women attending oncology daycare unit using validated survey questionnaire (PSS Tool): An institutional experience in central India
Presenter: Rajesh Patidar
Session: Poster Display
Resources:
Abstract
467P - Evaluation of the effectiveness of a cluster management model based on evidence-based concepts in oncology nutrition case management
Presenter: Li He
Session: Poster Display
Resources:
Abstract
468P - The patterns of use of Traditional Chinese Medicine (TCM) in cancer patients in Hong Kong
Presenter: Olivia L T Chan
Session: Poster Display
Resources:
Abstract
469P - The need of special care for adolescent and young adult (AYA) cancer survivors: Perspective from oncologists in India
Presenter: Nandini Menon
Session: Poster Display
Resources:
Abstract
470TiP - Randomised controlled trial to evaluate the efficacy and safety of moisturising creams with or without palm-oil-derived vitamin E concentrate in addition to urea-based cream or urea-based cream alone in Capecitabine-associated Palmar-Plantar Erythrodysesthesia (ECaPPE)
Presenter: Pei-Jye Voon
Session: Poster Display
Resources:
Abstract
471TiP - A group sequential, response-adaptive randomized double-blinded clinical trial to evaluate add-on olanzapine plus pregabalin to prevent chemotherapy-induced nausea and vomiting (CINV ) in patients belonging to low socio-economic status
Presenter: Mathan Ramasubbu
Session: Poster Display
Resources:
Abstract